Business Context and Reporting Period
Cormedix Inc. filed a Form 8-K Current Report on February 18, 2013, regarding a material definitive agreement entered into on the same date. The company is a Delaware corporation focused on the development and commercialization of its product, Neutrolin.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $533,000 from the sale of 761,429 shares of Series A Non-Voting Convertible Preferred Stock and a warrant to purchase 400,000 shares of common stock.
- Transaction Price: $0.70 per share for the Series A stock (sold together with the warrant).
- Warrant Terms: Exercise price of $1.50 per share; five-year term; exercisable immediately.
- Warrant Repurchase: The company agreed to repurchase 220,000 warrants from the same investor at $0.15 per warrant (total cost $33,000). These warrants had an exercise price of $3.4375.
- Use of Proceeds: General corporate purposes, development and commercialization of Neutrolin, working capital, and capital expenditures.
- Liquidity and Debt: The filing does not provide specific data on total debt, cash flow, or liquidity ratios. The transaction is intended to bolster working capital.
Material Changes and Structural Amendments
The company filed a Certificate of Designation with the Delaware Secretary of State to classify the Series A Non-Voting Convertible Preferred Stock. Key structural features include:
- Conversion Rights: Each Series A share converts to one common share at the holder's option, subject to a beneficial ownership limitation of 3.99%.
- Liquidation Preference: Holders receive $0.001 per share prior to common stockholders in the event of liquidation.
- Dividends: No dividends are payable unless specifically declared by the board.
- Ranking: Senior to common stock and any junior capital stock; pari passu with other Series A stock; junior to any senior capital stock.
Outlook, Risks, and Contingencies
The closing of the transactions was anticipated for February 19, 2013, subject to customary closing conditions. No placement agent or underwriter was involved. The filing notes that the sale of Series A shares and the warrant repurchase are not contingent on one another, though they are expected to close simultaneously. The securities are issued pursuant to a prospectus supplement under an effective shelf registration statement (Form S-3).
Investor Verification Checklist
- Verify the actual closing date and receipt of the $533,000 gross proceeds.
- Confirm the impact of the 3.99% beneficial ownership limitation on the investor's ability to convert or exercise warrants.
- Review the net proceeds after deducting the $33,000 cost for the warrant repurchase.
- Examine the filed Certificate of Designation (Exhibit 3.3) for full legal terms of the Series A stock.
- Monitor future filings for the prospectus supplement referenced in the report.